← Back to home

PD-L1-POSITIVE, LOCALLY ADVANCED (UNRESECTABLE STAGE IIIB/C) OR METASTATIC NSCLC

Clinical trials for PD-L1-POSITIVE, LOCALLY ADVANCED (UNRESECTABLE STAGE IIIB/C) OR METASTATIC NSCLC explained in plain language.

Never miss a new study

Get alerted when new PD-L1-POSITIVE, LOCALLY ADVANCED (UNRESECTABLE STAGE IIIB/C) OR METASTATIC NSCLC trials appear

Sign up with your email to follow new studies for PD-L1-POSITIVE, LOCALLY ADVANCED (UNRESECTABLE STAGE IIIB/C) OR METASTATIC NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for Tough-to-Treat lung cancer: experimental combo enters final testing

Disease control Ongoing

This trial is testing whether a new drug called acasunlimab, when combined with pembrolizumab, works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer. It is for patients whose cancer has spread, is PD-L1 positive, and has gotten wo…

Matched conditions: PD-L1-POSITIVE, LOCALLY ADVANCED (UNRESECTABLE STAGE IIIB/C) OR METASTATIC NSCLC

Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control

Last updated Mar 23, 2026 15:17 UTC

PD-L1-POSITIVE, LOCALLY ADVANCED (UNRESECTABLE STAGE IIIB/C) OR METASTATIC NSCLC

Get alerted when new PD-L1-POSITIVE, LOCALLY ADVANCED (UNRESECTABLE STAGE IIIB/C) OR METASTATIC NSCLC trials appear

New hope for Tough-to-Treat lung cancer: experimental combo enters final testing